Search

Your search keyword '"Yang, Yuan-Han"' showing total 575 results
Start Over Author "Yang, Yuan-Han"
575 results on '"Yang, Yuan-Han"'

12. High burden of cerebral white matter lesion in 9 Asian cities

Author

Lam, Bonnie Yin Ka, Yiu, Brian, Ampil, Encarnita, Chen, Christopher Li-Hsian, Dikot, Yustiani, Dominguez, Jacqueline C., Ganeshbhai, Patel Vishal, Hilal, Saima, Kandiah, Nagaendran, Kim, SangYun, Lee, Jun-Young, Ong, Anam Paulus, Senanarong, Vorapun, Leung, Kam Tat, Wang, Huali, Yang, Yuan-Han, Yong, Tingting, Arshad, Faheem, Alladi, Suvarna, Wong, Samuel, Ko, Ho, Lau, Alexander Yuk Lun, and Mok, Vincent Chung Tong

Published
2021
Full Text
View/download PDF

16. Quetiapine Oral Solution in Alzheimer's Disease: Efficacy and Dosage Insights from a Real-World Retrospective Study.

Author

Li, Kuan-Ying, Lin, Bin-Tse, Hsu, Shu-Ting, Chien, Ching-Fang, Chang, Yang-Pei, and Yang, Yuan-Han

Subjects
ALZHEIMER'S disease, QUETIAPINE, DRUG dosage, NEUROPSYCHOLOGICAL tests, ORAL drug administration
Abstract

Background: Neuropsychiatric symptoms (NPS) are distressing for patients with dementia, often accelerating functional decline and nursing home placement. Medications such as quetiapine are used to alleviate NPS, but their side effects require cautious use. Liquid formulations such as quetiapine oral suspension suit specific populations; however, real-world data on their use in patients with dementia are limited. Objective: The purpose of this retrospective, naturalistic study was to provide preliminary data on the effects of treatment with quetiapine oral suspension on behavioral and psychiatric disturbances in Alzheimer's disease (AD) outpatients in Taiwan. Methods: Between January 2022 and June 2023, data were collected from outpatients with a diagnosis of probable AD who received treatment with Qting® (quetiapine oral solution 25 mg/ml). Primary outcome measures were changes in Neuropsychiatric Inventory (NPI) total score and its sub-items from baseline to the endpoint. Results: We recruited 66 AD patients with a mean age of 72.1±7.6 years, most of whom were female (69.7%). Twenty-three patients had data on neuropsychological test and NPI scores before and after quetiapine treatment. There was no significant change in global cognitive function from baseline to the endpoint. A significant reduction in NPI total score after quetiapine treatment was noted, while the effect on NPI sub-items was limited. The average maintenance dose was 1.5±0.6 ml. Conclusions: We demonstrated our clinical experience of the use of quetiapine oral solution in AD patients with NPS. Our results showed that quetiapine oral solution treatment significantly improved these symptoms at a relatively low dose. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Optical Coherence Tomography Assessment of Macular Thickness in Alzheimer's Dementia with Different Neuropsychological Severities.

Author

Kao, Chia-Chen, Hsieh, Hui-Min, Chang, Yo-Chen, Chu, Hui-Chen, Yang, Yuan-Han, and Sheu, Shwu-Jiuan

Subjects
ALZHEIMER'S disease, OPTICAL coherence tomography, MINI-Mental State Examination, RETINAL imaging, GRIDS (Cartography)
Abstract

This retrospective case-control study aimed to investigate associations between disease severity of Alzheimer's dementia (AD) and macular thickness. Data of patients with AD who were under medication (n = 192) between 2013 and 2020, as well as an age- and sex-matched control group (n = 200) with normal cognitive function, were included. AD patients were divided into subgroups according to scores of the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR). Macular thickness was analyzed via the Early Treatment Diabetic Retinopathy Study (ETDRS) grid map. AD patients had significant reductions in full macula layers, including inner circle, outer inferior area, and outer nasal area of the macula. Similar retinal thinning was noted in ganglion cells and inner plexiform layers. Advanced AD patients (MMSE score < 18 or CDR ≥ 1) showed more advanced reduction of macular thickness than the AD group (CDR = 0.5 or MMSE ≥ 18), indicating that severe cognitive impairment was associated with thinner macular thickness. Advanced AD is associated with significant macula thinning in full retina and inner plexiform layers, especially at the inner circle of the macula. Macular thickness may be a useful biomarker of AD disease severity. Retinal imaging may be a non-invasive, low-cost surrogate for AD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

46. Plasma biomarkers and their correlation in adult children of parents with Alzheimer's disease

Author

Huang, Ling-Chun, Chen, Ming-Hui, Chuu, Chih-Pin, Li, Kuan-Ying, Hour, Tzyh-Chyuan, and Yang, Yuan-Han

Subjects
Aging, Cognitive Neuroscience
Abstract

Family history (FH) of late-onset Alzheimer’s disease (AD) is associated with changes in several cerebrospinal fluid (CSF) biomarkers in cognitively normal individuals. However, potential changes in plasma biomarkers remain unknown. This study aimed to evaluate potential plasma biomarkers and their correlation in cognitively normal adult children (AC) and to compare this data with their AD parents and unrelated non-demented controls (NC). Participants with dementia due to AD, their AC and NC were recruited. Plasma samples were assessed for amyloid beta (Aβ)1–42, Aβ1–40, total tau (T-tau) and phosphorylated tau (P-tau). Kruskal–Wallis test was used for the comparison of this data between the three groups. Spearman rank correlation was used for evaluation of the correlations between Aβ1–40 and Aβ1–42, and T-tau and P-tau in the AD and AC groups. A total of 99 subjects completed the assessment (30 had AD; 38 were AC group; and 31 were NC). Compared with the NC group, there were significantly higher levels of Aβ1–40, P-tau, and P-tau/T-tau ratio, and lower levels of Aβ1–42 and Aβ1–42/Aβ1–40 ratio in the AD and AC groups. The correlation between the level of Aβ1–42 and Aβ1–40 and level of T-tau and P-tau was only observed in the AC but not in the AD group. AC of AD parents demonstrate some indicators of AD like their parents. Disruption to the correlation between Aβ and tau in AD may be a biomarker for the development of AD in AC, which should be examined in a longitudinal cohort.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results